You are here

Article Text

Article menu
Download PDFPDF
Letter
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
  1. Sébastien Le Burel1,
  2. Stéphane Champiat2,3,
  3. Emilie Routier4,
  4. Sandrine Aspeslagh2,
  5. Laurence Albiges5,
  6. Tali-Anne Szwebel6,
  7. Jean-Marie Michot2,
  8. Pascale Chretien7,
  9. Xavier Mariette8,9,10,11,
  10. Anne-Laure Voisin12,
  11. Olivier Lambotte1,9,10,11
  1. 1Assistance Publique—Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie clinique, Le Kremlin-Bicêtre, France
  2. 2Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France
  3. 3INSERM, U981, Villejuif, France
  4. 4Département de dermatologie, Institut Gustave Roussy, Villejuif, France
  5. 5Département d'oncologie médicale, Institut Gustave Roussy, Villejuif, France
  6. 6Service de Médecine Interne, Assistance Publique—Hôpitaux de Paris, Hôpital Cochin, Paris, France
  7. 7Laboratoire d'Immunologie, Assistance Publique—Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  8. 8Service de Rhumatologie, Assistance Publique—Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  9. 9INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, France
  10. 10UMR 1184, Université Paris Sud, Le Kremlin-Bicêtre, France
  11. 11CEA, DSV/iMETI, IDMIT, Fontenay-aux-Roses, France
  12. 12Institut Gustave Roussy, Unité Fonctionnelle de Pharmacovigilance, Villejuif, France
  1. Correspondence to Professor Olivier Lambotte, CHU Bicêtre, APHP, Department of Internal Medicine and Clinical Immunology, 78 rue du Général Leclerc, Le Kremlin-Bicêtre F-94275, France; olivier.lambotte{at}aphp.fr

https://doi.org/10.1136/annrheumdis-2016-210820

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Although treatment with immune checkpoint inhibitors (ICIs) is associated with better survival in many cancer settings, these therapeutics can induce immune-related adverse events (IrAEs).1 ,2 REISAMICi is a French, prospective, multicentre, academic registry sponsored by the Gustave Roussy Institute cancer centre. The objective is to better detect, document and manage IrAEs.

    Connective tissue diseases (CTD) have not previously been reported in patients treated with anti-PD1/PDL-1 agents. The REISAMIC registry was screened for reports of CTD.

    Of the 447 patients supervised in the REISAMIC registry, three have developed CTD: two cases of Sjögren's syndrome and one case of cryoglobulinemic vasculitis as a complication of suspected Sjögren's syndrome (table 1). A case of ANA+ myositis registered in REISAMIC by another investigating centre …

    View Full Text

    Footnotes

    • Contributors OL, the corresponding author, states that all the authors listed have contributed to the work.

    • Funding LA: research funding: Novartis, Pfizer.

    • Competing interests Honoraria: SC for Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme and Roche. LA for Novartis, Pfizer, BMS, Sanofi and Ipsen. OL for Merck Sharp Dohme and Genzyme.

    • Ethics approval Gustave Roussy ethical committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • ↵i Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie.